

ATTACHMENT I - Sequence Listing

SEQUENCE LISTING

<110> COHEN, JOYAROM

SEP 21 2001

<120> Pharmaceutical Composition for the Treatment of Syndrom X of Reaven

<130> TPP30566

<140> 09/254,600

<141> 1999-03-11

<150> PCT/IL97/00301

<151> 1997-10-09

<150> IL 119250

<151> 1996-09-12

<150> IL 119403

<151> 1996-10-10

<160> 7

<170> PatentIn version 3.0

<210> 1

<211> 11

<212> PRT

<213> HUMAN

<220>

<221> SITE

<222> (1)..(1)

<223> XAA IS 7, AMINOHEPTANIOIC ACID

<400> 1

Xaa Lys Asn Phe Phe Trp Lys Thr Tyr Thr Ser  
1 5 10

<210> 2

<211> 12

<212> PRT

<213> HUMAN

<220>

<221> SITE

<222> (1)..(1)

<223> XAA IS DESAMINOCYSTEINNE RADICAL

<220>

<221> SITE

<222> (11)..(11)

<223> XAA IS THE RADICAL OF AN ALPHA-(LOWER ALKYL) AMINO-(LOWER ALKYL)-  
CARBOXYLIC ACID HAVING A MINIMUM OF 4 AND A MAXIMUM OF 8 CARBON A  
TOMS, IN WHICH THE TWO LOWER ALKYL RADICALS CAN BE CONNECTED TO O  
NE ANOTHER WIHT A SINGLE C-C BOND ..

<400> 2

Xaa Lys Asn Phe Phe Trp Lys Thr Phe Thr Xaa Cys  
1 5 10

<210> 3

<211> 8

<212> PRT

<213> HUMAN

<220>

<221> SITE

<222> (8) .. (8)

<223> XAA IS RESIDUE OF -AMINOBUTYRIC ACID SUBSTITUTED BY A CYCLIC HYDR  
OCARBYL RADICAL AR SELECTED FROM THE GROUP CONSISTING OF CYCLOHYX  
YL, PHENYL OPTIONALLY SUBSTITUTED BY HALOGEN, NITRO OR PHENOXY; A  
ND NAPTHYL OPTIONALLY SUBSTITUTED BY HAL

<400> 3

Asn Phe Phe Trp Lys Thr Phe Xaa  
1 5

<210> 4

<211> 6

<212> PRT

<213> HUMAN

D,  
<220>

<221> SITE

<222> (2) .. (2)

<223> XAA IS PHE TYR, 3 - (P-FLOUROPHEYL) ALANINE OR 3 (P-CHLOROPHENYL) ALAN  
INE RESIDU

<220>

<221> SITE

<222> (4) .. (4)

<223> LYS, LYS-C(1-8) (FLOURO) ALKYL

<220>

<221> SITE

<222> (5) .. (5)

<223> XAA IS THR, VAL, SER

<400> 4

Cys Xaa Trp Xaa Xaa Cys  
1 5

<210> 5  
<211> 12  
<212> PRT  
<213> HUMAN

<220>

<221> SITE

<222> (5) .. (5)

<223> XAA IS PHE TYR, 3-(P-FLOUROPHEYL)ALANINE OR 3(P-CHLOROPHENYL)ALANINE RESIDU

<220>

<221> SITE

<222> (8) .. (8)

<223> XAA IS THR, VAL, SER

<220>

<221> SITE

<222> (7) .. (7)

<223> LYS, LYS-C(1-8)(FLOURO)ALKYL

<400> 5

Cys Lys Asn Phe Xaa Trp Xaa Xaa Phe Thr Ser Cys  
1 5 10

<210> 6

<211> 14

<212> PRT

<213> HUMAN

<400> 6

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
1 5 10

<210> 7  
<211> 28  
<212> PRT  
<213> HUMAN

D1  
Concludes

<400> 7  
Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala Gly  
1 5 10 15  
Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
20 25

---